## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### Form 8-K

# Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 03/07/2007

## Tercica, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 000-50461

Delaware (State or other jurisdiction of incorporation) 26-0042539 (IRS Employer Identification No.)

#### 2000 Sierra Point Parkway

Suite 400

Brisbane, CA 94005

(Address of principal executive offices, including zip code)

(650) 624-4900

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Edgar Filing: TERCICA INC - Form 8-K

Information to be included in the report

#### Item 8.01. Other Events

On March 6, 2007, Tercica, Inc. (the "Company") issued a press release announcing that Tercica, Insmed and Genentech, Inc. have entered a Settlement, License and Development Agreement that resolves all outstanding litigation between the companies, including the patent infringement suits brought by Tercica and Genentech against Insmed in the United States (N.D. Cal.) and United Kingdom, and the unfair business practices suit (E.D. Virginia).

#### Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tercica, Inc.

Date: March 07, 2007 By: /s/ Stephen N. Rosenfield

Stephen N. Rosenfield Executive Vice President of Legal Affairs

## **Exhibit Index**

Exhibit No.	Description
EX-99.1	Press release entitled "Litigation Settlement Reached between Tercica, Genentech and Insmed", dated March 3, 2007